| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1220224 | Journal of Pharmaceutical and Biomedical Analysis | 2016 | 7 Pages |
•An HPLC method for a potent topoisomerase inhibitor, LMP776, was developed.•The HPLC method was validated to be stability-indicating per ICH guidelines.•A total of seven related compounds were characterized with LCMS.•One related compound was isolated and identified with NMR.
An HPLC method for the assay of a DNA topoisomerase inhibitor, LMP776 (NSC 725776), has been developed and validated. The stress testing of LMP776 was carried out in accordance with International Conference on Harmonization (ICH) guidelines Q1A (R2) under acidic, alkaline, oxidative, thermolytic, and photolytic conditions. The separation of LMP776 from its impurities and degradation products was achieved within 40 min on a Supelco Discovery HS F5 column (150 mm × 4.6 mm i.d., 5 μm) with a gradient mobile phase comprising 38–80% acetonitrile in water, with 0.1% trifluoroacetic acid in both phases. LC/MS was used to obtain mass data for characterization of impurities and degradation products. One major impurity was isolated through chloroform extraction and identified by NMR. The proposed HPLC assay method was validated for specificity, linearity (concentration range 0.25–0.75 mg/mL, r = 0.9999), accuracy (recovery 98.6–100.4%), precision (RSD ≤ 1.4%), and sensitivity (LOD 0.13 μg/mL). The validated method was used in the stability study of the LMP776 drug substance in conformance with the ICH Q1A (R2) guideline.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
